Janssen-Cilag

Contact
janssen-cilag.es
+34917228100

Janssen-Cilag S.A.

Pº de las Doce Estrellas, 5-7
28042 Madrid
Spain
+34917228100
janssen-cilag.es
Contact
Profile News
Contact

About Janssen-Cilag

Read more about Janssen-Cilag
Facts about Janssen-Cilag
  • Focus : Manufacturer
  • Industry : Pharma

News about Janssen-Cilag

Janssen-Cilag

15-Jun-2020 | research and development

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

Phase 1/2a Clinical Trial to Begin in Second Half of July

Read news
Janssen-Cilag

05-Jul-2012 | research and development

Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)

The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of ...

Read news
Janssen-Cilag

13-Sep-2010 | research and development

Discontinuation of sale of ceftobiprole in Switzerland

Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the ...

Read news
Janssen-Cilag

29-Jun-2010 | research and development

European CHMP concludes re-examination of ceftobiprole

Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV, a Johnson & Johnson ...

Read news
Janssen-Cilag

23-Feb-2010 | research and development

European CHMP adopts negative opinion on ceftobiprole

Basilea Pharmaceutica Ltd. announced that the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing ...

Read news
Janssen-Cilag

02-Sep-2008 | research and development

INTELENCE (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy

The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) (etravirine). INTELENCE is a next ...

Read news
Janssen-Cilag

19-Jun-2007 | research and development

Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole

Basilea Pharmaceutica Ltd. announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by ...

Read news
Show more news about Janssen-Cilag

Here you will find Janssen-Cilag S.A.